glp-1 and dual glp-1/gip receptor agonists Triple Gut Peptide on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data | Current Obesity Reports glp 1 gip dual agonist

Description

Some people experience persistent fatigue , headaches , or anxiety that does not resolve with dose adjustments

Hayashi D et al

However, GLP-1 can act as a helpful addition especially for patients who: Have obesity or are overweight Have type 2 diabetes or metabolic syndrome Need improvements in multiple metabolic risk factors (not just cholesterol) Who Benefits Most The cholesterol and lipid benefits of GLP-1 tend to be greater in: People who lose significant weight on it Those with elevated triglycerides to start Patients with insulin resistance or type 2 diabetes Individuals implementing lifestyle changes (diet, physical activity, etc.) alongside medication What to Expect & Important Things to Know Timeframe : Changes in lipid levels usually show up over months not immediately

A notable RCT is the pioglitazone in early PD trial, which failed to demonstrate the possibility of pioglitazone delaying disease progression in early-stage PD patients [38]